Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma

Steven P. Rowe, Michael A. Gorin, Hans J. Hammers, Martin G. Pomper, Mohammad E. Allaf, Mehrbod Som Javadi

Research output: Contribution to journalArticle

30 Scopus citations


Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.

Original languageEnglish (US)
Pages (from-to)83-85
Number of pages3
JournalClinical Nuclear Medicine
Issue number1
StatePublished - Jan 1 2016



  • metastatic renal cell carcinoma
  • PET/CT
  • prostate-specific membrane antigen (PSMA)

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this